Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported net income was CNY 352.51 million compared to CNY 575.63 million a year ago. Basic earnings per share from continuing operations was CNY 0.0713 compared to CNY 0.1165 a year ago. Diluted earnings per share from continuing operations was CNY 0.0713 compared to CNY 0.1165 a year ago.